PMID: 7025685Jan 1, 1981Paper

Trial of daunomycin in acute promyelocytic leukemia of childhood: a Southwest Oncology Group Study

The American Journal of Pediatric Hematology/oncology
J van EysM Duncan

Abstract

Children with acute promyelocytic leukemia were treated with aggressive daunomycin induction and 6-mercaptopurine and methotrexate maintenance. The remission rate was 8 out of 10 fully evaluable patients. Three are still alive up to 32 months. With vigorous induction therapy, occurrence of disseminated intravascular coagulation was rare. Only one case of DIC was seen in a child who had pseudomonas sepsis at time of diagnosis. Since current protocols are more aggressive, future chemotherapy include patients with acute promyelocytic leukemia.

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.